Masrour-Roudsari Jila, Hasanjani-Roushan Mohammadreza, Yahyapour Yousef, Barari-Savadkoohi Rahim, Bijani Ali, Sadeghi Farzin, Mohammadnia-Afroozi Mousa
Student Research Committee, Babol University of Medical Sciences, Babol, Iran.
Infectious Diseases and Tropical Medicine Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran.
Caspian J Intern Med. 2020;11(2):205-210. doi: 10.22088/cjim.11.2.205.
Hepatitis B Surface antigen (HBsAg) seroclearance and seroconversion (development of antibodies against HBsAg) can increases the survival of Chronic hepatitis B (CHB) patients. The aim of this study was to determine the percentage and timing of HBsAg seroclearance and seroconversion in patients with chronic hepatitis B infection.
1026 patients with CHB infection who referred to a private clinic were included. These patients had been followed-up for an average of 15 years. The patients whose HBs Ag was cleared from the blood and remained negative until the end of follow-up were designated as HBs Ag serocleared and the patients whose HBs Ab was positive during follow-upwas designated as HBs Ag seroconverted. The time of seroclearance and seroconversion of patients was recorded. Liver function tests, alpha-fetoprotein (AFP) and Hepatitis B early antigen (HBe Ag) status were extracted from the patients' medical records. Data were analysis with SPSS 17.
The duration of follow-up was from 2 to 410 months and most patients were males (58.2%).The survival rate of HBs Ag positivity after 5, 10 and 15 years were 95.6, 89.4 and 80.7%, and 98, 93.5 and 84.9% of patients had not yet developed anti-HBs antibodies after 5, 10 and 15 years, respectively. Age, gender and taking medication had no effect on HBs Ag clearance from the blood or anti-HBs production.
The HBs Ag seroconversion is a rare occurrence, but the incidence of this may increase with time, age and drug consumption. Though there was no relationship in our patients.
乙肝表面抗原（HBsAg）血清学清除及血清学转换（产生抗HBsAg抗体）可提高慢性乙型肝炎（CHB）患者的生存率。本研究旨在确定慢性乙型肝炎感染患者HBsAg血清学清除及血清学转换的百分比和时间。
纳入1026例到一家私人诊所就诊的CHB感染患者。这些患者平均随访了15年。血液中HBsAg清除且直至随访结束仍保持阴性的患者被指定为HBsAg血清学清除，随访期间HBsAb呈阳性的患者被指定为HBsAg血清学转换。记录患者血清学清除和血清学转换的时间。从患者病历中提取肝功能检查、甲胎蛋白（AFP）和乙肝e抗原（HBeAg）状态。数据用SPSS 17进行分析。
随访时间为2至410个月，大多数患者为男性（58.2%）。5年、10年和15年后HBsAg阳性的生存率分别为95.6%、89.4%和80.7%，5年、10年和15年后分别有98%、93.5%和84.9%的患者尚未产生抗HBs抗体。年龄、性别和用药对血液中HBsAg清除或抗HBs产生没有影响。
HBsAg血清学转换很少见，但随着时间、年龄和药物消耗，其发生率可能会增加。尽管在我们的患者中没有这种关系。
